Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

Final draft guidance: 1

Final draft guidance (PDF 201 KB)

Committee papers (PDF 1.95 MB)

Draft guidance

Draft guidance (online commenting)

Committee papers - ACM1 (PDF 7.67 MB)

Public committee slides - ACM1 (PDF 871 KB)

Equality impact assessment (PDF Version) - Draft Guidance (PDF 148 KB)

Final scope (PDF 225 KB)

Final stakeholder list (PDF 164 KB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 193 KB)

Draft matrix post referral (PDF 163 KB)